
    
      Participants will receive a primary vaccination consisting of three doses of ACTACEL at
      either 2, 3, and 4 months of age or at 3, 4, and 5 months of age; or Wuhan DTaP and Act-HIB
      vaccines at 3, 4, and 5 months of age. All participants will receive a single booster dose at
      18-20 months of age and will be followed up for one month after the last dose of study
      vaccine.
    
  